Want to see GB:AREC full AI Analyst Report?
Arecor Therapeutics PLC (AREC) AI Stock Analysis
Arecor Therapeutics PLC
(LSE:AREC)
The overall score is held down primarily by weak and volatile financial performance, with ongoing operating losses and persistent cash burn despite an improved balance sheet and strong gross margins. Technicals provide a moderate positive offset, as the stock maintains an underlying uptrend with controlled volatility but lacks strong bullish momentum. Valuation further constrains the score, since a high P/E on non-durable earnings and no dividend offers limited compensation for the company’s execution and funding risks.
Arecor Therapeutics PLC (AREC) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 37.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 33.10K
- Price to Earnings (P/E)
- 165.0
- Beta (1Y)
- 0.69
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arecor Therapeutics PLC Business Overview & Revenue Model
Company Description
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of...
Arecor Therapeutics PLC Financial Statement Overview
Summary
Financial performance is weak but improving: revenue is highly volatile with a recent sharp drop, operating losses persist despite a one-off move to net profit, and cash flow remains materially negative, while the de-levered balance sheet and stronger gross margins provide some offsetting strength.
Income Statement
42NeutralBalance Sheet
58NeutralCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -95.00K | 1.71M | 5.05M | 4.57M | 2.40M | 1.16M |
| Gross Profit | 760.00K | 1.05M | 1.54M | 4.57M | 2.40M | 1.16M |
| EBITDA | -5.18M | -4.45M | -10.15M | -8.39M | -10.06M | -6.27M |
| Net Income | 190.00K | 664.00K | -10.24M | -8.55M | -9.26M | -6.17M |
Balance Sheet | ||||||
| Total Assets | 4.65M | 8.10M | 8.72M | 15.38M | 21.77M | 20.92M |
| Cash, Cash Equivalents and Short-Term Investments | 3.15M | 6.13M | 3.26M | 6.75M | 12.81M | 18.32M |
| Total Debt | 57.00K | 98.00K | 232.00K | 338.00K | 288.00K | 231.00K |
| Total Liabilities | 966.00K | 1.65M | 3.37M | 5.85M | 4.31M | 2.37M |
| Stockholders Equity | 3.68M | 6.45M | 5.35M | 9.53M | 17.45M | 18.55M |
Cash Flow | ||||||
| Free Cash Flow | -4.48M | -2.39M | -9.18M | -5.99M | -11.13M | -5.52M |
| Operating Cash Flow | -4.45M | -2.29M | -9.15M | -5.84M | -10.78M | -5.45M |
| Investing Cash Flow | 4.33M | 2.38M | 1.72M | 6.52M | -7.99M | -68.00K |
| Financing Cash Flow | -129.00K | -148.00K | 5.65M | -180.00K | 5.16M | 20.93M |
Arecor Therapeutics PLC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AREC, the sentiment is Positive. The current price of 85.00 is above the 20-day moving average (MA) of 79.63, above the 50-day MA of 78.99, and above the 200-day MA of 70.38, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 64.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AREC.
Arecor Therapeutics PLC Peers Comparison
Overall Rating
GB:BVXP89Outperform- GB:AREC49.4Neutral
GB:FAB49Neutral
GB:AVCT43Neutral
GB:OXB43Neutral
GB:APTA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:BVXP | 89Outperform | GBP 104.50M | 14.14 | 67.81% | 7.32% | -1.10% | 0.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:AREC | 49Neutral | GBP 37.37M | 165.00 | 3.75% | ― | ― | ― |
| GB:FAB | 49Neutral | GBP 7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% |
| GB:AVCT | 43Neutral | GBP 294.51M | -6.44 | -1293.07% | ― | ― | ― |
| GB:OXB | 43Neutral | GBP 652.29M | -15.39 | -54.51% | ― | 15.97% | 3.72% |
| GB:APTA | 37Underperform | GBP 10.23M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:AREC | Arecor Therapeutics PLC | 82.50 | 10.00 | 13.79% | |
| GB:AVCT | Avacta Group plc | 58.70 | -12.80 | -17.90% | |
| GB:BVXP | Bioventix plc | 2050.00 | 32.34 | 1.60% | |
| GB:OXB | Oxford Biomedica (otc) | 532.00 | -150.00 | -21.99% | |
| GB:FAB | Fusion Antibodies Plc | 6.00 | -6.75 | -52.94% | |
| GB:APTA | Aptamer Group Plc | 0.28 | -0.53 | -65.24% |
Arecor Therapeutics PLC Corporate Events
Arecor Extends Global Patent Cover for Next-Generation Insulins in Automated Delivery
PositiveArecor Therapeutics has secured expanded international intellectual property protection for AT278, its ultra-concentrated, ultra-rapid-acting insulin, in key markets including Europe, the U.S. and India. The new patents cover use of AT278 in automate...
Arecor to Present Half-Year Results as It Advances Next-Generation Diabetes Therapies
PositiveArecor Therapeutics plc, a Cambridge-based clinical-stage biotech, is developing ultra-rapid, concentrated insulins and an oral peptide delivery platform aimed at reducing treatment burden and improving outcomes in diabetes, obesity and wider cardiom...
Arecor Raises £5.13m in Oversubscribed Retail and Placing Offer
PositiveArecor Therapeutics has completed an oversubscribed retail share offer, issuing 191,176 new shares at 68 pence and raising about £0.13 million in gross proceeds. Together with a previously completed placing, the fundraising will deliver approxim...
Arecor Raises £5m in Share Placing to Extend Cash Runway and Fund Insulin Programmes
PositiveArecor Therapeutics has raised approximately £5.0 million through a conditional placing of 7,352,941 new ordinary shares at 68 pence each with institutional and professional investors. The new capital is intended to strengthen its balance sheet,...
Arecor Launches Retail Share Offer After £5m Placing
PositiveArecor Therapeutics plc is a clinical-stage biotechnology company listed on AIM that develops enhanced therapeutics aimed at reducing treatment burden and improving outcomes for people with diabetes, obesity and other cardiometabolic diseases. The co...
Arecor Closes Order Book for Accelerated Equity Placing
PositiveArecor Therapeutics plc has closed its accelerated bookbuild placing to new orders, marking the completion of the order-taking phase in its latest equity fundraising process. The company plans to announce the final result of the placing and the timet...
Arecor launches £5.13m share fundraising to drive next‑generation insulin development
PositiveArecor Therapeutics plc has launched a proposed fundraising of up to £5.13 million via a placing of approximately 7.35 million new shares at 68 pence and a separate retail offer of up to 191,176 shares to qualifying UK shareholders. The new shar...
Arecor advances insulin partnerships and launches funding amid wider losses
NeutralArecor Therapeutics reported interim results for the six months to 30 June 2026, highlighting progress in its diabetes franchise as partnering talks with multiple insulin pump companies for its insulin-AID combinations reached term sheet stage. Co-de...
Arecor’s AT278 Data Published, Underscoring Ultra-Rapid Potential in High-Dose Diabetes Care
PositiveArecor Therapeutics announced that full clinical results from its AT278-104 trial have been published in the peer-reviewed journal Diabetes, Obesity & Metabolism, providing external validation for its lead ultra-concentrated insulin candidate. Th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026